Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Adelaide, South Australia. The company went IPO on 2011-02-11. The firm owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Sa Zinc, Jervois Domain, Blueys and Inkheart Lead/Silver, Bynoe Gold, Fitton Uranium, and Napperby Uranium. Shoobridge Lithium project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. Sa Zinc project covers a total area of approximately 500 km2 in northern South Australia. Jervois Domain project covers three exploration licenses in the central Northern Territory.

Vanguard Australian Shares Index Etf

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Brainchip Holdings Ltd

BRN

BrainChip Holdings Ltd. engages in the development of software and hardware solutions for artificial intelligence and machine learning applications. The company is headquartered in Sydney, New South Wales and currently employs 66 full-time employees. The company went IPO on 2011-11-09. The principal activity of the Company is the development of software and hardware accelerated solutions for advanced artificial intelligence (AI) and machine learning applications with a primary focus on the development of its Neuromorphic Processor IP, Akida, to provide a complete ultra-low power and fast AI Edge network for vision, audio, olfactory and smart transducer applications. Its products include MetaTF, Akida1000 reference chip and Akida Enablement Platforms. The MetaTF development environment is a machine learning framework used for the creation, training, and testing of neural networks, supporting the development of systems for Edge AI on its Akida event domain neural processor. The Akida1000 reference chip is fully functional and enables working system evaluation. Its Akida Enablement Platforms include Akida PCIe Board, Akida Development Kit Shuttle PC and Akida Development Kit Raspberry Pi.

Incannex Healthcare Limited

IHL

Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The firm is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The firm targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. The company is investigating the use of psilocybin-assisted psychotherapy to treat GAD.